Sharon Kochan Operating Director

  • EducationTechnion Institute of Management
    Columbia University
    Tel-Aviv University
  • ExperiencePadagis LLC
    President Prescription Pharmaceuticals
    Agis Industries
  • Board RolesApotex

Mr. Sharon Kochan served as President and CEO of Padagis LLC from its incorporation in July 2021, when it was carved out of Perrigo Company Plc. (“Perrigo”), a global, over-the-counter, consumer goods and specialty pharmaceutical company listed on the New York Stock Exchange, until February 2023, and has served as a consultant to Padagis until the end of 2023.

Prior to that, Mr. Kochan served as Executive Vice President & President Pharmaceuticals from 2018 for Perrigo, President International, from 2012 until 2018, and President Prescription Pharmaceuticals from 2007. From 2005 to 2007, Mr. Kochan served as Senior Vice President of Business Development and Strategy for Perrigo. Mr. Kochan was Vice President, Business Development of Agis Industries (1983) Ltd. (“Agis”) from 2001 until Perrigo acquired Agis in 2005. Mr. Kochan has served as a board member of MediWound Ltd. (NASDAQ MDWD) from June 2017 to July 2023 and served as a board member of Exalenz BioScience Ltd. from July 2016 to March 2020 when it was acquired by Meridian. Mr. Kochan has been serving on the board of Solgel Technologies Inc. (NASDAQ SLGL) since July 2023 and currently serves as a member of the Board of Directors of Apotex.

Mr. Kochan completed the Senior Management Program at the Technion Institute of Management in Haifa, Israel, received a Master of Science in Operations Research & Management Science from Columbia University in New York City, and received a Bachelor of Science in Industrial Engineering from Tel-Aviv University, Israel.

Operating Directors are not employees of SK Capital. Such directors are expected to receive compensation from certain Funds’ portfolio investments and/or directly from certain Funds. Such compensation will not result in offsets to, or reductions of the management fee paid by the corresponding Fund.